Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Alter, Galit
    • Other Affiliation: Beth Israel Deaconess Medical Center
  • Yu, Jingyou
    • Other Affiliation: Beth Israel Deaconess Medical Center
  • Liu, Jinyan
    • Other Affiliation: Beth Israel Deaconess Medical Center
  • Chandrashekar, Abishek
    • Other Affiliation: Beth Israel Deaconess Medical Center
  • Borducchi, Erica N.
    • Other Affiliation: Beth Israel Deaconess Medical Center
  • Tostanoski, Lisa H.
    • Other Affiliation: Beth Israel Deaconess Medical Center
  • McMahan, Katherine
    • Other Affiliation: Beth Israel Deaconess Medical Center
  • Jacob-Dolan, Catherine
    • Other Affiliation: Beth Israel Deaconess Medical Center
  • Martinez, David R.
    • Affiliation: University of North Carolina at Chapel Hill
  • Chang, Aiquan
    • Other Affiliation: Beth Israel Deaconess Medical Center
  • Anioke, Tochi
    • Other Affiliation: Beth Israel Deaconess Medical Center
  • Lifton, Michelle
    • Other Affiliation: Beth Israel Deaconess Medical Center
  • Nkolola, Joseph
    • Other Affiliation: Beth Israel Deaconess Medical Center
  • Stephenson, Kathryn E.
    • Other Affiliation: Beth Israel Deaconess Medical Center
  • Atyeo, Caroline
    • Other Affiliation: Ragon Institute of MGH, MIT and Harvard
  • Shin, Sally
    • Other Affiliation: Ragon Institute of MGH, MIT and Harvard
  • Fields, Paul
    • Other Affiliation: Adaptive Biotechnologies
  • Kaplan, Ian
    • Other Affiliation: Adaptive Biotechnologies
  • Robins, Harlan
    • Other Affiliation: Adaptive Biotechnologies
  • Amanat, Fatima
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Krammer, Florian
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Baric, Ralph S.
    • Affiliation: University of North Carolina at Chapel Hill
  • Le Gars, Mathieu
    • Other Affiliation: Janssen Vaccines & Prevention
  • Sadoff, Jerald
    • Other Affiliation: Janssen Vaccines & Prevention
  • de Groot, Anne Marit
    • Other Affiliation: Janssen Vaccines & Prevention
  • Heerwegh, Dirk
    • Other Affiliation: Janssen Research & Development
  • Struyf, Frank
    • Other Affiliation: Janssen Research & Development
  • Douoguih, Macaya
    • Other Affiliation: Janssen Vaccines & Prevention
  • van Hoof, Johan
    • Other Affiliation: Janssen Vaccines & Prevention
  • Schuitemaker, Hanneke
    • Other Affiliation: Janssen Vaccines & Prevention
  • Barouch, Dan H.
    • Other Affiliation: Beth Israel Deaconess Medical Center
Abstract
  • The Ad26.COV2.S vaccine1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains unclear. Here we report humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals from the COV1001 phase 1/2 clinical trial2 against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1., and B.1.351 variants of concern. Ad26.COV2.S induced median pseudovirus neutralizing antibody titers that were 5.0- and 3.3-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020 on day 71 following vaccination. Median binding antibody titers were 2.9- and 2.7-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020. Antibody-dependent cellular phagocytosis, complement deposition, and NK cell activation responses were largely preserved against the B.1.351 variant. CD8 and CD4 T cell responses, including central and effector memory responses, were comparable among the WA1/2020, B.1.1.7, B.1.351, P.1, and CAL.20C variants. These data show that neutralizing antibody responses induced by Ad26.COV2.S were reduced against the B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants. These findings have implications for vaccine protection against SARS-CoV-2 variants of concern.
Date of publication
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • Nature
Language
  • English
Version
  • Postprint
ISSN
  • 1476-4687

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details s41586-021-03681-2_reference.pdf 2021-07-07 Public Download